Logo do repositório
 

Circulating miR-16-5p, miR-92a-3p, and miR-451a in plasma from lung cancer patients: Potential application in early detection and a regulatory role in tumorigenesis pathways

dc.contributor.authorReis, Patricia P. [UNESP]
dc.contributor.authorDrigo, Sandra A. [UNESP]
dc.contributor.authorCarvalho, Robson F. [UNESP]
dc.contributor.authorLapa, Rainer Marco Lopez
dc.contributor.authorFelix, Tainara F. [UNESP]
dc.contributor.authorPatel, Devalben
dc.contributor.authorCheng, Dangxiao
dc.contributor.authorPintilie, Melania
dc.contributor.authorLiu, Geoffrey
dc.contributor.authorTsao, Ming-Sound
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionInstituto de Investigación
dc.contributor.institutionUniversity Health Network
dc.contributor.institutionUniversity of Toronto
dc.contributor.institutionPrincess Margaret Cancer Centre
dc.date.accessioned2020-12-12T01:33:03Z
dc.date.available2020-12-12T01:33:03Z
dc.date.issued2020-08-01
dc.description.abstractBackground: Micro(mi)RNAs, potent gene expression regulators associated with tumorigenesis, are stable, abundant circulating molecules, and detectable in plasma. Thus, miRNAs could potentially be useful in early lung cancer detection. We aimed to identify circulating miRNA signatures in plasma from patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), and to verify whether miRNAs regulate lung oncogenesis pathways. Methods: RNA isolated from 139 plasma samples (40 LUAD, 38 LUSC; 61 healthy/non-diseased individuals) were divided into discovery (38 patients; 21 controls for expression quantification using an 800-miRNA panel; Nanostring nCounter®) and validation (40 patients; 40 controls; TaqMan® RT-qPCR) cohorts. Elastic net, Maximizing-R-Square Analysis (MARSA), and C-Statistics were applied for miRNA signature identification. Results: When compared to healthy individuals, 580 of 606 deregulated miRNAs in LUAD and 221 of 226 deregulated miRNAs in LUSC had significantly increased levels. Among the 10 most significantly overexpressed miRNAs, 6 were common to patients with LUAD and LUSC. Further analysis identified three signatures composed of 12 miRNAs. Signatures included miRNAs commonly overexpressed in patient plasma. Enriched pathways included target genes modulated by three miRNAs in the C-Statistics signature: miR-16-5p, miR-92a-3p, and miR-451a. Conclusions: The 3-miRNA signature (miR-16-5p, miR-92a-3p, miR-451a) had high specificity (100%) and sensitivity (84%) to predict cancer (LUAD and LUSC). These miRNAs are predicted to modulate genes and pathways with known roles in lung tumorigenesis, including EGFR, K-RAS, and PI3K/AKT signaling, suggesting that the 3-miRNA signature is biologically relevant in adenocarcinoma and squamous cell carcinoma of the lung.en
dc.description.affiliationFaculty of Medicine São Paulo State University UNESP
dc.description.affiliationExperimental Research Unity São Paulo State University UNESP
dc.description.affiliationDepartment of Structural and Functional Biology Institute of Biosciences São Paulo State University UNESP
dc.description.affiliationUniversidad Católica Los Ángeles de Chimbote Instituto de Investigación
dc.description.affiliationPrincess Margaret Cancer Centre University Health Network
dc.description.affiliationDepartment of Medical Biophysics University of Toronto
dc.description.affiliationDepartment of Medical Oncology and Hematology Princess Margaret Cancer Centre
dc.description.affiliationDepartment of Laboratory Medicine and Pathobiology University of Toronto
dc.description.affiliationLaboratory Medicine Program University Health Network
dc.description.affiliationUnespFaculty of Medicine São Paulo State University UNESP
dc.description.affiliationUnespExperimental Research Unity São Paulo State University UNESP
dc.description.affiliationUnespDepartment of Structural and Functional Biology Institute of Biosciences São Paulo State University UNESP
dc.description.sponsorshipPrincess Margaret Cancer Foundation
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipHealth Research Foundation
dc.description.sponsorshipIdFAPESP: # 2016/09021-9
dc.description.sponsorshipIdHealth Research Foundation: FDN-148395
dc.format.extent1-16
dc.identifierhttp://dx.doi.org/10.3390/cancers12082071
dc.identifier.citationCancers, v. 12, n. 8, p. 1-16, 2020.
dc.identifier.doi10.3390/cancers12082071
dc.identifier.issn2072-6694
dc.identifier.scopus2-s2.0-85088795038
dc.identifier.urihttp://hdl.handle.net/11449/199184
dc.language.isoeng
dc.relation.ispartofCancers
dc.sourceScopus
dc.subjectBiomarkers
dc.subjectLiquid biopsy
dc.subjectLung adenocarcinoma
dc.subjectLung cancer
dc.subjectLung squamous cell carcinoma
dc.subjectLung tumorigenesis
dc.subjectMicroRNAs
dc.subjectPathways
dc.subjectPlasma
dc.titleCirculating miR-16-5p, miR-92a-3p, and miR-451a in plasma from lung cancer patients: Potential application in early detection and a regulatory role in tumorigenesis pathwaysen
dc.typeArtigopt
dspace.entity.typePublication
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt

Arquivos